ArticleAging and disease2025
Microglial Histaminergic Signaling Promotes Interleukin-10 Production and Ameliorates Motor Dysfunction in Parkinson's Disease.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histamine functions as a neurotransmitter regulating multiple neural processes, whereas interleukin-10 (IL-10) is an anti-inflammatory cytokine with recognized neuroprotective properties. Previous research suggests that histamine can stimulate the release of various inflammatory mediators, including IL-10. However, the precise molecular mechanisms governing the interaction between histamine and IL-10, particularly their role in safeguarding dopaminergic neurons in Parkinson's disease (PD), have not been fully elucidated. The current findings suggest that, within the context of PD, histamine levels are elevated in the substantia nigra pars compacta (SNc) microglia, leading to an upregulation of IL-10 expression through activation of the H2 receptor and the downstream cAMP/PKA/p38β/CREB signaling cascade. However, the increased histamine concentration was negatively regulated by the IL-10 expression, allowing a limited increase in its concentration. Furthermore, the H2R-IL-10 pathway activation inhibited microglial activation and the production of inflammatory factors. Moreover, the H2R-IL-10 signaling axis modulated both membrane resistance and the expression of cleaved caspase-3 mRNA in dopaminergic neurons, contributing to the improvement of motor deficits in LPS-induced mouse models. These observations suggest that, in the pathological context of PD, microglia in the SNc exhibit increased production of histamine and IL-10 in a mutually regulatory manner. Elevated histamine levels further enhance IL-10 expression, which confers neuroprotection to dopaminergic neurons through its anti-inflammatory actions, ultimately alleviating motor impairments associated with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.